Cargando…
Review of various NAMPT inhibitors for the treatment of cancer
Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD salvage pathway of mammalian cells and is overexpressed in numerous types of cancers. These include breast cancer, ovarian cancer, prostate cancer, gastric cancer, colorectal cancer, glioma, and b-cell lymphoma. NAMP...
Autores principales: | Wei, Yichen, Xiang, Haotian, Zhang, Wenqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490061/ https://www.ncbi.nlm.nih.gov/pubmed/36160449 http://dx.doi.org/10.3389/fphar.2022.970553 |
Ejemplares similares
-
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
por: Galli, Ubaldina, et al.
Publicado: (2020) -
Visfatin/PBEF/Nampt: A New Cardiovascular Target?
por: Peiró, Concepción, et al.
Publicado: (2010) -
From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases
por: Zhu, Yumeng, et al.
Publicado: (2022) -
Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity
por: Lynn, Heather, et al.
Publicado: (2023) -
Data on metabolic stability, aqueous solubility and CYP inhibition of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors
por: Aprile, Silvio, et al.
Publicado: (2019)